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Abstract 
The definition of acute-on-chronic liver failure (ACLF) remains contested. In Europe 
and America, the term is generally applied according to the European Association for 
the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium guidelines to a 
syndrome that develops in patients with cirrhosis and is characterized by acute 
decompensation, organ failure and high short-term mortality. One-third of patients who 
are hospitalized for acute decompensation present with ACLF at admission or develop 
the syndrome during hospitalization. ACLF frequently occurs in closed temporal 
relationship to a precipitating event, such as bacterial infection or acute alcoholic, drug-
induced or viral hepatitis. However, in approximately 40% of patients no precipitating 
event can be identified. The mechanism of ACLF involves systemic inflammation due 
to infections, acute liver damage, and, in cases without precipitating events, probably 
 4 
 
intestinal translocation of bacteria or bacterial products. ACLF is graded into three 
stages (ACLF grades 1-3) on the basis of the number of organ failures, with higher 
grades associated with increased mortality. Liver and renal failure are the most 
common organ failures, followed by coagulation, brain, circulatory and respiratory 
failure. The 28-day mortality rate associated with ACLF is 30%. Depending on the 
grade, ACLF can be reversed using standard therapy in only 16-51% of patients, 
leaving a considerable proportion of patients with ACLF that remains steady or 
progresses. Liver transplantation in selected patients with ACLF grade 2 and ACLF 
grade 3 increases the 6-month survival from 10% to 80%.  
[H1] Introduction  
 Cirrhosis is a progressive chronic liver disease characterized by diffuse fibrosis, 
severe disruption of the intrahepatic venous flow, portal hypertension and liver failure. 
The course of cirrhosis is divided into two stages1  (Figure 1). Compensated cirrhosis 
defines the period between the onset of cirrhosis and the first major complication. 
During this period, which is relatively long in most patients (>10 years), symptoms are 
absent or minor, but liver lesions and portal pressure steadily progress. The term 
decompensated cirrhosis defines the period following the development of ascites (that 
is, the accumulation of large amounts of fluid within the peritoneal cavity), variceal 
haemorrhage and/or hepatic encephalopathy2–4. This period is associated short-term 
survival (3-5 years).  
Concepts about cirrhosis are rapidly changing. First, cirrhosis is no longer considered 
to be an irreversible progressive disease. Indeed, decompensated cirrhosis may return 
to compensated cirrhosis or even to pre-cirrhotic phases if the cause of the disease is 
removed5. Second, the list of organ dysfunctions in cirrhosis (hepatic, circulatory, renal 
and cerebral) has been expanded to include the immune system, intestine, heart, lung, 
adrenal glands, muscles and thyroid gland. Third, new mechanisms involved in the 
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pathogenesis of cirrhotic complications, such as dysbiosis of the microbiota6 and 
systemic inflammation7 have been recognized. Finally, it is increasingly evident that 
patients rarely die as a consequence of an end-stage irreversible destruction of the 
liver. Rather, in most patients the cause of death is an acute deterioration in their 
clinical condition promoted by a precipitating event — a syndrome termed acute-on-
chronic liver failure (ACLF)8. 
More than 13 distinct definitions of ACLF have been proposed. These definitions are 
generally based on personal experience or consensus agreements9–15 (Box 1).  
The Asia-Pacific Association for the Study of the Liver (APASL) definition has received 
major attention (Box 1)11,12. This definition is based on positive and negative criteria. 
Main positive criteria are: prior diagnosis of chronic liver disease (cirrhotic or non-
cirrhotic, excluding isolated steatosis); a precipitating event that has a direct effect on 
the liver; acute hepatic insult; causing acute liver failure. Main negative criteria in the 
APASL definition are: no prior history of acute decompensation in patients with 
cirrhosis (decompensated cirrhosis would represent the presence of end-stage 
progressive liver disease); and no extra-hepatic precipitating event such as bacterial 
infection. The APASL definition was based on a consensus conference.  
The APASL proposal did not reach wide diffusion in Europe and America for several 
reasons. First, the most common form of ACLF in these areas occurs in patients with 
decompensated cirrhosis in closed chronological relationship with bacterial infections 
or active alcoholism8,13 (Figure 1) and these patients are not included in the APASL 
definition. Second, the concept that decompensated cirrhosis represents a terminal 
phase of the disease is not the experience of European centres. Third, extrahepatic 
organ failure is the most characteristic differential feature between patients with ACLF 
vs those with acute decompensation in the European patients. Finally, ACLF in patients 
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with non-cirrhotic chronic liver disease is exceptional in Europe and America due to the 
low prevalence of hepatitis A, B and C. 
For these reasons, in 2009 the European Association for the Study of the Liver-Chronic 
Liver Failure (EASL-CLIF) Consortium started a prospective multicentre European 
observational study in 1,343 patients who were hospitalized for acute decompensation 
of cirrhosis (the CANONIC study). This study was aimed to define ACLF in cirrhosis, to 
assess the prevalence and clinical course of the syndrome and to improve the 
accuracy of the prognostic scores currently available 8,16–20 through an evidence-based 
pragmatic approach. The analysis of this study lead to a new definition with three major 
characteristics (Box 1): Acute decompensation of cirrhosis; the presence of organ 
failure(s) (either hepatic or extrahepatic); and a high probability of short-term (28-day) 
mortality. Following the publication of the main articles derived from the CANONIC 
study, the definition, grading of severity of ACLF and prognostic scores proposed are 
widely used in Europe, Asia and America for the assessment/treatment of patients with 
decompensated cirrhosis 21–32.  
It has been suggested that differences between APASL and EASL-CLIF Consortium 
definitions are logical consequences of the distinct epidemiology of liver diseases 
between the East and in the West28,33. However, the differences are more likely to be 
related to the distinct objectives by which both definitions were designed. The ACLF 
definition by the APASL consensus group was designed to identify a condition that 
anticipates the development of extrahepatic or multi-organ failure and death11,12. By 
contrast, the goal of the CANONIC study was to characterize a syndrome in which 
organ failure(s) and high short-term mortality are central features8.  
Attempts to unify both definitions have been not successful34. Recent investigations 
from Asia have compared the two definitions in large series of patients with 
cirrhosis22,26,35. Figure 2 compares the results of the largest Asian series35 with those in 
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the CANONIC study8. A coincident diagnosis by the APASL and the EASL-CLIF 
Consortium definitions was observed in only a minority of patients in both series, 
indicating that the two ACLF definitions selected different patient populations (Figure 
2a). The EASL-CLIF Consortium definition was significantly more accurate in predicting 
prognosis than the APASL definition both in the East and the West. The EASL 
definition was also better to predict prognosis (Figure 2b). Significant differences in 
mortality depending on the diagnostic criteria were also observed in two other cohorts 
of patients from China and India23,26.  This Primer on ACLF in cirrhosis uses the EASL-
CLIF Consortium definition. The reader is referred to a Review by Sarin and 
Choudhury36 for a discussion of ACLF that is based the APASL criteria. 
 
[H1] Epidemiology  
 [H2] Worldwide prevalence and mortality  
ACLF is a major worldwide medical problem, with prevalence rates in at-risk 
populations in the region of 20-35% (Table 1). The worldwide reported mortality of 
ACLF according to the EASL-CLIF Consortium definition ranges between 30% and 
50% and correlates closely with the number of organ failures. In Europe, the average 
28-day mortality rate without liver transplant reported by the CANONIC study was 1.9% 
in patients with decompensated cirrhosis without ACLF and 32.8% in patients with 
ACLF (23% in patients with ACLF grade 1, 31% in patients with ACLF grade 2 and 
74% in patients with ACLF grade 3; see Box 2 for details)8.  
 
In the United States, a study using the North-American Consortium for the Study of 
End Stage Liver Disease (NACSELD criteria) (Box 1) reported that the 30-day mortality 
rate associated with infected decompensated cirrhosis without ACLF was 8% and this 
 8 
 
rate increased to 27%, 49%, 64% and 77% in patients with one, two, three and four 
organ failures, respectively13. In addition, in the United States, no significant reduction 
in mortality in patients with ACLF has been observed over the past two decades, with 
mortality in the nationwide sample approaching 50%32.  
 
In China, the average 28-day transplant free mortality reported by Li et al. in patients 
with decompensated cirrhosis due to chronic hepatitis B virus (HBV) infection was 
2.6% in patients without ACLF and 44% in patients with ACLF (EASL-CLIF Consortium 
definition) (23.6%, 40.8% and 60.2% in patients with ACLF grade 1, 2 and 3 
respectively, Box 2 for details)37. Zang el al. reported similar findings in Chinese 
patients with decompensated cirrhosis of different aetiologies23. The 90-day mortality 
rate in patients with no ACLF and with ACLF grade 1, 2 and 3 were 2.1% 39.9% 54.1% 
and 84.7% (EASL-CLIF Consortium definition), respectively23.  
 
[H2] Precipitating events  
Precipitating events of ACLF vary according to geographical areas, and can be 
classified as hepatic or extra-hepatic depending on their site of origin (Figure 1) 14,34,37–
39. Reactivation of chronic hepatitis B, acute hepatitis A or hepatitis E virus infection38, 
acute alcoholic hepatitis and acute bacterial infection are the most frequent 
precipitating events of ACLF in Asia23. In the West, the most common precipitating 
events are active alcoholism and bacterial infections, although in a considerable 
proportion of patients there is no recognizable precipitating event8. The potential role of 
drug-induced liver injury as precipitating event in ACLF has been insufficiently explored 
both in the East and in the West. 
 
[H2] Organ failures  
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In the CANONIC study, among the different organ and system failures in ACLF, the 
most frequently affected organs or systems were kidneys (55.8% of patients) followed 
by liver (43.6% of patients), coagulation (27.7% of patients), brain (24.1% of patients), 
circulation(16.8% of patients) and lungs(9.2% of patients). At first glance, it might be 
surprising that not all patients with ACLF had liver failure, but there are two important 
issues that should be taken into account. First, the level of bilirubin used to define liver 
failure was very high (≥12 mg per dL), and most (if not all) patients without liver failure 
also have abnormal bilirubin values, which implies a variable degree of impairment of 
liver function in these patients. Second, it is important to note that definition of ACLF 
goes beyond the classical concept of decompensation of cirrhosis and includes the 
consequences of cirrhosis on the function of other organs7.  
 
[H1] Mechanisms/pathophysiology 
[H2] ACLF during course of Cirrhosis  
As indicated, cirrhosis is a progressive disease that inevitably leads to death unless the 
aetiological mechanism is suppressed by appropriate treatment or a liver transplant is 
performed. Indeed, there is good evidence that  discontinuation of alcohol ingestion in 
alcoholic cirrhosis, antiviral treatment in chronic hepatitis B and C cirrhosis and immune 
suppressive therapy in autoimmune cirrhosis may transform decompensated cirrhosis 
to compensated cirrhosis or even to pre-cirrhotic phases5. In contrast, if the etiological 
mechanisms persists in patients with compensated cirrhosis, hepatic fibrosis increases 
progressively as a consequence of continuous liver cell necrosis and inflammation, 
giving rise to progressive distortion of the liver architecture, reduction in liver 
parenchyma cells, increase in the intrahepatic resistance to the portal venous flow, 
portal hypertension, liver insufficiency and acute decompensation of the disease 
(Figure 1).  
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The development of complications, mainly ascites and, less frequently, variceal 
haemorrhage or hepatic encephalopathy, marks the onset of decompensated 
cirrhosis., which is characterized by impairment in the function of the liver and 
extrahepatic organs and systems, including the brain (disturbances affecting cognitive, 
psychiatric and motor functions ranging from subclinical alterations to severe stupor 
and coma), kidney (impairment in renal sodium and free water excretion, intrarenal 
haemodynamics, renal perfusion and glomerular filtration rate), circulation (splanchnic 
arterial vasodilation leading to reduction in systemic vascular resistances and high 
cardiac output), lungs (impairment in the ventilation/perfusion ratio leading to hypoxia 
and hypocapnia), heart (impairment in chronotropic and left ventricular systolic and 
diastolic functions), coagulation (due to impairment in the hepatic synthesis of 
coagulant and anticoagulant factors and increased fibrinolysis), adrenal glands 
(impaired ability to provide adequate cortisol release in response to stress), intestines 
(reduced motility, bacterial overgrowth and increased permeability of the mucosal 
barrier leading to increased translocation of bacteria and/or bacterial products from the 
intestinal lumen to the systemic circulation), immune system (systemic inflammation 
and impaired function of polymorphonuclear leukocytes and monocytes), thyroid glands 
(impaired hormonal secretion) and muscles (sarcopenia) (Figure 1). 
ACLF may develop at any phase of the disease from compensated to early or late 
decompensated cirrhosis (Figure 1). It is, therefore, not a terminal event of a long-
standing decompensated cirrhosis.  As indicated above (Box 2), organ failure as 
defined by an intense impairment in the function of six specific organs or systems that 
are important in determining prognosis  (the liver, kidneys and brain and the 
coagulation, circulatory and respiratory systems8 is the differential feature of ACLF 
versus decompensated cirrhosis without ACLF. By contrast, organ dysfunction, which 
defines a less severe impairment in the function of these (and other) organs and 
systems, is the differential feature of decompensated cirrhosis versus compensated 
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cirrhosis. For instance, according to the CANONIC study brain failure is defined by a 
hepatic encephalopathy grade 3 or 4 of the West Haven classification whereas brain 
dysfunction is defined by a hepatic encephalopathy grade 1 or 2. Renal dysfunction is 
defined by a serum creatinine of 1.5-1.9 mg/dl whereas renal failure is defined be a 
serum creatinine ≥ 2 mg/dl. 
[H2] Inflammation in ACLF  
ACLF is associated with features of systemic inflammation. For example, white blood 
cell count and plasma levels of C-reactive protein (CRP) and pro-inflammatory 
cytokines and chemokines such as interleukin (IL)-6, IL-1β, IL-8 are higher in patients 
with ACLF compared to patients with cirrhosis but not ACLF8,22. Moreover, among 
patients with ACLF, the higher the ACLF severity, as estimated by the number of organ 
failures, the higher plasma pro-inflammatory cytokine/chemokine levels (V. Arroyo, 
unpublished results, CANONIC study). The excessive systemic production of pro-
inflammatory cytokines and chemokines — or ‘cytokine storm’ — by the patient’s 
immune system might cause collateral tissue damage40, a process termed 
immunopathology41. As such, a cytokine storm might also be a prominent contributor to 
the development of organ failures in patients with cirrhosis. Of note, in with patients 
with ACLF, a subset of CD14-positive monocytes exhibit overexpression of the 
tyrosine-protein kinase Mer (encoded by MERTK) which results in the inhibition of the 
production of inflammatory cytokines by these cells22, suggesting that a form of 
compensatory immune suppression develops in parallel to the systemic inflammatory 
response.  
 
There are two categories of ACLF: those in which the inducer(s) of inflammation (for 
example, bacterial infection or excessive alcohol intake) are identified and those in 
which there is no clinically identifiable trigger(s)8. Here, the latter category is called 
‘ACLF with no clinically identifiable trigger’ Inducers of inflammation are either 
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exogenous or endogenous42. Among exogenous inducers we will discuss only bacterial 
inducers because the others are beyond the scope of this Primer and have been 
described elsewhere42. Although much of the molecular detail of how inflammation 
triggers ACLF remains to be elucidated, it is likely that the following general processes 
play a key part. “Bacterial inducers of inflammation” and “endogenous inducers of 
inflammation” are potential mechanisms of inflammation in ACLF.   
 
[H3] Bacterial inducers of inflammation. 
Bacterial pathogens can induce inflammation through two distinct classes of molecules: 
pathogen-associated molecular patterns (PAMPs)42–44 and virulence factors42,45. 
PAMPs are recognized by the host via dedicated receptors called pattern-recognition 
receptors (PRRs), and examples of PRRs for bacterial ligands are detailed in Figure 
3A42–44.  The engagement of PRRs results in the stimulation of signalling cascades that 
activate transcription factors 43. PRR-activated transcription factors can induce an array 
of genes encoding molecules involved in inflammation, including pro-inflammatory 
cytokines (Figure 3B) 43,45,46. 
The second class of bacterial inducers of inflammation includes a large number of 
virulence factors42,44. Unlike PAMPs, most of these factors are generally not recognized 
by dedicated receptors but can be sensed via the effects of their activity (a process 
called functional feature recognition)38,46–48.    
 
[H3] Endogenous inducers of inflammation. 
Endogenous inducers are released by necrotic cells or produced by extracellular matrix 
(ECM) breakdown in an injured tissue (such as the diseased liver in the case of 
ACLF42,43, and are called danger-associated molecular patterns (DAMPs)49. DAMPs 
can be recognized by certain receptors of the host, with this recognition resulting in 
‘sterile’ inflammation. For example, high mobility group box 1 protein (HMGB1) 
 13 
 
engages the advanced glycation end-product-specific receptor (RAGE), which 
cooperates with Toll-like receptors (TLRs, a class of PRR) to induce an inflammatory 
response42,43,49. Additional factors that might also be involved in ACLF include  necrotic 
cells, which may release members of the IL-1 family such as IL-1α and IL-33 that 
trigger inflammation though their respective MyD88-coupled cognate receptors50.  
 
 [H3] Outcomes of the inflammatory response. 
The purpose of the inflammatory response to bacterial infection is to promote host 
resistance by reducing bacterial burden while that of sterile inflammation is to promote 
tissue repair51–54. However, when these two categories of inflammatory responses are 
excessive, they may induce tissue damage52. During bacterial infection, the acute 
phase of the inflammatory response can be excessive and cause immunopathology. 
For example, effectors of the immune response such as recruited neutrophils and 
inflammatory monocytes, activated Th1 and Th17 cells, and cytotoxic T cells are known 
to be associated with high risk of immunopathology44. There are also some examples 
of DAMP-induced excessive inflammatory response causing major tissue damage. 
Mice deficient for Ripk1 develop Ripk3-Mlkl-mediated necroptosis resulting in systemic 
inflammation, multiorgan injury and death within 3 days of birth50. In this model, the IL-
33 (a DAMP) drives systemic inflammation and severity. Therefore, the initial tissue 
injury caused by necroptosis may result in further tissue damage. In the context of 
severe bacterial infection, cell necrosis can occur (as a feature of immunopathology) 
and result in DAMP release. In this case released DAMPs can perpetuate or 
accentuate inflammation originally triggered by bacterial inducers (PAMPs and 
virulence factors)51.  
 
[H2] ACLF with identified inducers of inflammation 
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The relative contribution of these inflammatory processes to ACLF likely differ 
depending on the trigger, and considerable research is still needed to fully elucidate the 
aetiological pathways of this syndrome. Of all the recognised precipitating events in 
ACLF, the mechanisms underlying two — sepsis and severe alcoholic hepatitis — are 
best-characterized and will be detailed below.  
 
[H3] Sepsis-induced ACLF. 
Organ-dysfunction caused by a dysfunctional host immune response to bacterial 
infection defines sepsis-induced ACLF”.  Thirty percent of patients with cirrhosis and 
ACLF have bacterial sepsis as an identifiable trigger of the syndrome8. However, ACLF 
can also predispose to bacterial infection: indeed, a proportion of patients with ACLF 
develop bacterial infection during the course of the syndrome8. Among bacterial 
infections, spontaneous bacterial peritonitis (SBP), sepsis and pneumonia were more 
frequently associated with ACLF than other infections in the CANONIC study. In 
patients with cirrhosis and ascites, viable intestinal bacteria can cross the intestinal 
barrier and migrate to the general circulation and colonize the ascitic fluid55,56. 
 
During the first hours of bacterial infection, patients with cirrhosis have higher plasma 
levels of pro-inflammatory cytokines than patients without cirrhosis. This finding 
suggests the existence of excessive inflammation in cirrhosis57,58. The mechanisms 
that underlie this excessive inflammatory response to bacterial infection are 
incompletely understood59. In fact, most of our knowledge is based on experiments 
investigating the innate immune response to lipopolysaccharide (LPS), a PAMP 
recognized by TLR459–61 (Figure 3). The response to LPS has been studied in ex vivo 
studies performed in freshly isolated monocytes or peripheral blood mononuclear cells 
(PBMCs) from patients with and without cirrhosis. LPS-stimulated production of pro-
inflammatory cytokines and chemokines is higher in cells from patients with cirrhosis 
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than in control cells62–66. The mechanisms of the LPS-induced “cytokine storm” 
associated with cirrhosis are poorly understood. Ex-vivo experiments have shown that 
PBMCs or monocytes from patients with cirrhosis exhibit defects in the following 
negative-feedback mechanisms of TLR4 signalling: the activation of the 
phosphatidylinositide3-kinase (PI3K)/ RAC-alpha serine/threonine-protein kinase (AKT) 
pathway61,65; inhibition of glycogen synthase kinase 3 activity66; and the induction of IL-
1 receptor-associated kinase M (IRAK-M)62 and of the anti-inflammatory cytokine IL-
1061,65. Nevertheless, several other crucial mechanisms known to downregulate the 
TLR-mediated inflammatory response under non-cirrhotic conditions (in particular the 
induction of tumour necrosis factor, alpha-induced protein 3 (A20)) have not yet been 
investigated in the context of cirrhosis.  
Following in vivo LPS challenge, plasma TNF levels are significantly higher in cirrhotic 
than in non-cirrhotic animals67–71. Moreover, in this setting, animals with but not without 
cirrhosis develop hepatocyte apoptosis and necrosis70. In addition, compared with 
normal livers, in cirrhotic livers LPS also elicits prolonged endoplasmic reticulum (ER) 
stress and a subsequent unfolded protein response that is responsible for sustained 
phosphorylation of eukaryotic translation initiation factor 2 subunit α (eIF-2-α) 70. EIF-2-
α phosphorylation is known to attenuate the translation of most RNAs 72. In this context, 
hepatocyte TNF-mediated cell death might occur in cirrhotic livers because of the lack 
of translation of NF-κB-dependent survival mRNAs into proteins. In support of this 
hypothesis, normal hepatocytes exposed to high levels of TNF are protected against 
cell death because of the induction of NF-κB-dependent pro-survival proteins73. 
Together, these findings led to the theory that, in cirrhosis, LPS recognition might result 
in severe liver damage which is due not only to an excessive innate immune response 
but also to the impairment of mechanisms involved in hepatocyte ER homeostasis.  
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Future studies should investigate the inflammatory response and tissue damage 
induced by the recognition of PAMPs other than LPS. It should also be noted that the 
role of inducers of inflammation, other than PAMPs, such as virulence factors and 
DAMPs have not yet been studied in the context of sepsis-induced ACLF. 
 
[H3] Severe alcoholic hepatitis. 
Results of the CANONIC study suggest that 20% of cases of ACLF are caused by 
severe alcoholic hepatitis8. In alcoholic hepatitis, livers exhibit features of cell death and 
inflammation74,75. However, the underlying mechanisms that explain these features are 
still poorly understood75, and most of the following mechanisms commented hereafter 
require confirmation.  
 
Excessive alcohol consumption alters the gut microbiota and increases intestinal 
permeability75. In addition, chronic and excessive systemic inflammation causes 
damage to the intestinal barrier. These alterations might favour the translocation of 
bacteria into the bloodstream 76–78 (Figure 4). Regardless of whether these bacteria 
cause infection, they release PAMPs (such as LPS) which can reach the liver where 
they are recognized by TLRs expressed in resident macrophages (called Kupffer cells). 
This recognition stimulates the production of pro-inflammatory CXCL chemokines such 
as  IL-879 that attract and activate neutrophils80. Neutrophil infiltration is a hallmark of 
alcoholic hepatitis75. Hepatocyte necrosis, which has been documented in severe 
alcoholic hepatitis81, might result in the release of DAMPs that would be recognized by 
different receptors mediating an inflammatory response, as described above.  
 
Mitochondrial DNA (mtDNA) is a type of DAMP, and mtDNA stress might also 
contribute to inflammation in the context of alcoholic hepatitis. Acetaldehyde 
metabolism results in hepatocyte reactive oxygen species (ROS) production68. ROS 
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production is also stimulated by TNF65. In the context of chronic alcohol consumption82 
or after LPS challenge83, ROS overproduction induces mtDNA stress. In a mouse 
model of moderate mtDNA stress, mtDNA was shown to escape to the cytosol where it 
engaged a cell-intrinsic response involving the innate cytosolic DNA sensor cyclic 
GMP-AMP synthase (cGAS) (Figure 3A). cGAS engagement with mtDNA, in turn, 
mediates type 1 IFN production and subsequent autocrine and paracrine induction of 
IFN target genes84. Therefore, a cell-intrinsic response to mtDNA stress might become 
an inflammatory response at tissue level and thereby contribute to liver failure. 
Recent results suggest that the inhibition of liver regeneration might be involved in liver 
failure associated with severe alcoholic hepatitis85. Although hepatic progenitor cells 
are activated in livers with severe alcoholic hepatitis, these cells are committed to 
differentiate into cholangiocytes (epithelium lining the bile duct) instead of 
hepatocytes85. As a result, there might be no replacement of hepatocytes that die 
owing to alcoholic hepatitis. Together these findings suggest that severe alcoholic 
hepatitis might be caused by both immunopathology and impaired hepatocyte 
regeneration. 
 
[H2] ACLF with no identifiable trigger.   
The trigger of ACLF is unknown in approximately 40% of cases8. Although these 
patients show features of systemic inflammation8, one cannot clearly explain how the 
systemic inflammation is stimulated. Three hypotheses might explain inflammation in 
ACLF with no clinically identifiable trigger. These hypotheses try to explain the 
mechanisms of inflammation in patients in whom ACLF develop in the absence of any 
obvious trigger  
 
The first hypothesis is based on the existence of dysbiosis of the gut microbiota in 
patients with cirrhosis (Figure 4). Dysbiosis associated with cirrhosis is typically 
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characterized by a decrease in diversity, a decrease in Lachnospiraceae, 
Ruminococcaceae, Bacteroidaceae, Family XIV Incertae Sedisat the family level, and 
in Bacteroides at the genus level6,86–89. In addition, dysbiosis associated with cirrhosis 
involves an increase in Gram-negative Enterobacteriaceae, Fusobacteriaceae and 
Porphyromonadaceae, and Gram-positive Streptococcaceae at the family level6,86–89. 
Decompensation of cirrhosis results in additional distinct compositional changes of the 
microbiota when compared to compensated stages of liver disease87. There is a robust 
positive correlation between the abundance of certain bacterial family members and 
plasma levels of inflammatory cytokines (including IL-6 and TNF  in patients with 
ACLF90. These findings suggest that metabolites produced by gut microbiota might 
contribute to systemic inflammation (Figure 4).  
 
The second hypothesis is that some patients might have intestinal translocation of 
PAMPs such as LPS or bacterial CpG DNA91 (Figure 3A). These ligands might reach 
the liver and systemic circulation and then be recognized by TLRs. Thus, TLR 
recognition is generally not dependent on microbial viability or invasiveness. During the 
peak phase of ACLF, systemic levels of LPS are higher than prior to the onset of ACLF 
and during remission of survivors87,91, suggesting that higher systemic LPS levels 
correlate with disease severity. Interestingly, small intestinal bacterial overgrowth is a 
risk factor for increased systemic LPS levels in patients with cirrhosis92. Increased 
systemic levels of CpG DNA are found in patients with decompensated cirrhosis and 
without overt bacterial infection and correlate with mortality93, suggesting that CpG 
DNA rises may be involved in the development of ACLF in patients with acutely 
decompensated cirrhosis.  
 
The third mechanism explaining inflammation in ACLF with no clinically identifiable 
trigger might be the release of DAMPs, for example by necrotic hepatocytes. In 
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patients and animals with acute liver failure, a variety of DAMPs such as HMGB1 that 
might contribute to inflammation are released 83, but nothing is known about DAMPs in 
patients with ACLF.  
 
Finally, another possible explanation for a failure to identify a precipitating event in 
ACLF could relate to a failure of current diagnostic tests or the testing protocol to 
identify infection or DILI.  
 
[H1] Diagnosis, screening and prevention  
[H2] Defining organ failure and ACLF  
[H3] Diagnostic criteria of organ failure. 
One of the assumptions made to define the EASL-CLIF criteria is that extrahepatic 
organ failure(s) is a major differential feature of ACLF. The Chronic Liver Failure 
Sequential Organ Failure Assessment (CLIF-SOFA) score was the original scale used 
to define organ failure in the CANONIC study8. It was derived from the SOFA score, a 
scale widely used in intensive care16–19, which was then adapted to patients with 
chronic liver disease on the basis of published studies. Cut-off values were established 
after assessing the risk increase of 28-day mortality rates in each of the last four CLIF-
SOFA score categories compared to that of the previous one in the patients enrolled in 
the CANONIC study. A simplified version of the CLIF-SOFA score, the CLIF 
Consortium Organ Failure (CLIF-C OF) score (Table 2), with identical criteria to 
diagnose organ failure and similar prognostic accuracy has been developed20. 
 
[H3] Mortality criteria. 
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Another pre-defined criterion for the diagnosis of ACLF in the development of the 
EASL-CLIF criteria was an expected 28-day mortality rate ≥15%. In the CANONIC 
series, this criterion was present in patients with ≥2 organ failures, but not in patients 
with one organ failure (28-day mortality 14.6%). Additional risk factors were used to 
further categorize patients in this low-risk subgroup. This analysis produced subgroups 
of patients that fulfilled the three predefined criteria for ACLF (Figure 5): Patients with 
≥2 organ failures; patients with one organ failure (specifically kidney failure); and 
patients with non-renal single organ failure if these failures are associated with renal 
and/or cerebral dysfunction.  
 
[H2] Grades of severity of ACLF 
Patients with decompensated cirrhosis can be stratified into four groups of severity — 
no ACLF or ACLF grades 1-3 — on the basis of the type and number of organ failures 
they exhibit (Box 1). Kidney failure is the most prevalent organ failure in ACLF grade 1. 
For ACLF grade 2, liver failure is the most prevalent followed by kidney, cerebral and 
coagulation failure. For ACLF grade 3, the prevalence of all organ failures is high. 
In the CANONIC study, 23% of patients admitted to hospital had ACLF at admission. 
Furthermore, 11% of patients developed the syndrome during hospitalization, which 
gives a total prevalence of ACLF of 31%. Among patients with ACLF, 51% had ALCF 
grade 1, 35% ACLF grade 2 and 13% ACLF grade 3. Besides providing the diagnosis 
of the syndrome, these criteria also provide data for rapid prognostic information, with 
ACLF grade associated with different rates of mortality (Table 3). The usefulness of 
these classification criteria as well as that of CLIF-SOFA and CLIF-C OF scores  in 
assessing prognosis have been validated in independent series of patients26,29–31,94,95.  
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[H2] Natural history of ACLF 
ACLF is a syndrome that has potential for reversibility96. However, data from the 
CANONIC study clearly show that, despite this feature, mortality of ACLF patients 
increases cumulatively even after these patients are discharged from the hospital such 
that the mortality increases from approximately 20% at 28 days to over 35% at 90-days 
in patients with ACLF grade 1 and 30% to about 50% at 90-days in patients with ACLF 
grade 28. Although there is considerable variability between patients 20,21, some broad 
principles regarding the course of the condition can be put forward. In general, at day 
3-7 from presentation, approximately 50% patients with ACLF grade 1 will improve to 
having no ACLF, with a consequent 28-day mortality rate of approximately 7%. In 25% 
ACLF grade 1 will remain unchanged with a 28-day mortality rate of 24%. By contrast, 
approximately 25% patients with ACLF grade 1 progress to ACLF grade 2 or ACLF 
grade 3; their 28-day mortality is 53% and 88%, respectively. In patients presenting 
with ACLF grade 2, only 35% improve to having no ACLF or ACLF-1 at day 3-7 post-
presentation. Those that do improve have low 28-day mortality rates of approximately 
5%. In addition, approximately 50% of patients with ACLF grade 2 deteriorate to ACLF 
grade 3 (28-day mortality: 90%) or remain the same (28 day mortality: 26%). In patients 
presenting with ACLF grade 3, mortality rates remain very high with only approximately 
13% improving to no ACLF or ACLF grade 1. The factors that were independently 
related to progression to more advanced grades were the CLIF-C ACLF score 
(discussed below) and the presence of liver failure. These data indicate that the 
syndrome is indeed very dynamic and that early intervention is crucial to minimize the 
risk of death.  
 
[H2] Clinical risk factors  
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There are evidences that clinical course of ACLF outlined above is true for all 
aetiologies of ACLF. In a retrospective study from China in patients who predominantly 
had hepatitis-B related cirrhosis, short-term outcomes, the most closely associated with 
ACLF, were not affected by the nature of the precipitating illness97. Patients with 
hepatic precipitants such as reactivation of HBV or flares had a short-term (28-day and 
90-day) mortality similar than patients with an extrahepatic precipitant such as 
infection. This was also observed in a second Chinese study in HBV cirrhotic patients 
who developed ACLF. The 28-day and 90-day mortality rates for any given grade of 
ACLF in this study 24 were similar to those reported by the CANONIC study  and 
unrelated with the presence and type of precipitating events (Table 4).  These studies, 
therefore, suggest that it is the number of organ failures and not the aetiology of 
cirrhosis or precipitating event the main risk factor of mortality.  
A previous history of episodes of acute decompensation was absent in 23% of patients 
with ACLF in the CANONIC study, indicating that development of ACLF as the initial 
manifestation of decompensated cirrhosis is a relatively common feature. These 
patients without prior history of decompensation were younger, more frequently 
alcoholics, had more severe systemic inflammation and grade of ACLF and higher 
short-term mortality (42% vs 30%) than patients with ACLF and prior history of acute 
decompensation.  
 [H2] Prediction of prognosis 
Since ACLF is a dynamic syndrome, prognostic scores need to be dynamic so that 
they can be updated sequentially on a daily basis, which would allow assessment of 
response to intervention, escalation for the need for urgent liver transplantation and 
determination of futility of ongoing treatment. The CANONIC study indicates that follow-
up data within the first 3-7 days following diagnosis of ACLF are extremely important to 
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predict clinical course since resolution; improvement or worsening of ACLF following 
standard medical therapy occur within this early time period in most patients96. 
A prognostic model was developed and validated for patients with ACLF, referred to as 
the CLIF-C ACLF score, and for patients with acute decompensation who did not fulfil 
criteria for the diagnosis of ACLF, which is called the CLIF-C Acute Decompensation 
(CLIF-C AD; www.clifconsortium.com) score. These two scores were designed 
because a single score was insufficient to satisfactorily delineate the prognosis 
associated with acute decompensation and ACLF8. 
The CLIF-C ACLF score comprises the CLIF-C OF score, age and white blood cell 
count20,98. The score is a number from 0-100; the higher the number, the greater the 
risk of death. The score was validated using prospectively collected data from a series 
of patients not included in the CANONIC study. The CLIF-C ACLF score provided a 
significantly better estimate of the risk of death at 28-days, 90-days, 6-months and 12-
months post-presentation compared with the Model for End-Stage Liver Disease 
(MELD) score, the MELD-Sodium score and the Child Pugh score 24,32,95,99–101. 
Compared with the CLIF-C ACLF score, the MELD score underestimated the risk of 
death of patients by 20-30%, implying that organ allocation for transplants using the 
MELD score seriously disadvantages the patient with ACLF20. The performance of the 
CLIF-C ACLF score improved over the period of follow up suggesting that it should be 
updated daily20 (20).  
The CLIF-C AD score was developed in patients with acute decompensation without 
ACLF98. Variables that were found to be independently associated with survival were 
age, serum sodium level, serum creatinine level, white blood cell count and INR. These 
generated a score between 0-100 which was also significantly more accurate in 
predicting prognosis than the MELD, MELD-sodium and Child-Pugh scores24,98. 
Patients with a CLIF-C AD score of <45% had 28-day mortality of <3% and this 
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category might identify a group of patients that can be discharged early from the 
hospital. On the other hand, patients with CLIF-C AD score >60 were at high risk of 
progression to full-blown ACLF and had a 28-day mortality of approximately 20%, 
indicating that this is probably a ‘Pre-ACLF’ group. The CLIF-C AD score was also 
validated for sequential use. 
 
[H2] Prevention  
Early diagnosis and treatment of potential precipitating events are essential in the 
prevention of ACLF, and several preventative measures have been shown to be 
effective5,55,102–105. These all involve treating infections before they can go on to trigger 
ACLF and include: prompt administration of antibiotics tailored according to local 
epidemiological pattern of resistance in patients with suspected infections; long-term 
term suppression of HBV infection or sustained eradication of hepatitis C virus infection 
in patients with compensated or decompensated cirrhosis; and intravenous 
administration of albumin at infection diagnosis in patients with SBP. Albumin is highly 
effective preventing the development of type 1 Hepatorenal syndrome (HRS), a special 
form of ACLF characterized by rapidly progressive renal failure, in patients with SBP 
probably as a consequence of plasma volume expansion and also through a 
modulatory effect of albumin on the systemic inflammation associated with PAMPS (i.e. 
LPS) 104,105. There is no evidence that intravenous albumin is effective in other bacterial 
infections106,107. 
 
There is also indirect evidence in support of other potential preventive measures for 
ACLF. For example, long-term oral norfloxacin administration reduces the rate of SBP 
(and of other bacterial infections) and type-1 hepatorenal syndrome (HRS) in patients 
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with decompensated cirrhosis55,102,108–110. Norfloxacin acts by selectively reducing the 
Gram-negative microbiota, decreasing the permeability of the gut barrier via stimulation 
of IL-10 release and modulating the immune response to bacterial translocation111–113. 
In addition, treatment of patients with severe acute alcoholic hepatitis with 
pentoxifylline, an inhibitor of macrophage production of TNF, or with the combination of 
prednisolone and intravenous N-acetylcysteine  has been shown to reduce the 
incidence of type-1 HRS in some studies114,115, presumably by modulating hepatic 
inflammation,  but this has not confirmed in a recent investigation116.  Finally, short-term 
administration of the combination of granulocyte colony-stimulating factor (G-CSF) plus 
darbopoietin (a synthetic analogue of erythropoietin has been shown to improve liver 
function, reduce the incidence of severe sepsis and increase 1-year survival in 
comparison to placebo in patients with decompensated cirrhosis117.  
 
[H1] Management 
 [H2] Medical Management 
Medical management of ACLF consists of early recognition, treatment of the 
precipitating event and supportive care8,14,118,119. Early treatment of the trigger is proven 
to reduce mortality, for example in treatment of reactivated hepatitis B with tenofovir or 
alcoholic hepatitis with steroids75,117,119–121. However, most of ACLF management is 
focused on supportive care118 
 
[H3] Anti-bacterial therapy.  
As discussed above, bacterial infections are the precipitating event of ACLF in 
approximately 35% of patients (Table 4)14. As such, there should be a low threshold for 
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early initiation of antibiotics in patients with cirrhosis who have a bacterial infection. In 
patients with septic shock, every hour delay beyond presentation is associated with an 
adjusted odds of overall death of 1.1122,123. Broad spectrum antibiotics should be used, 
particularly in those with nosocomial or healthcare associated infections or in those 
with septic shock, as inappropriate initial antimicrobial therapy increases the adjusted 
odds of death by 10-fold122,123. Equally important to early initiation of antibiotics is 
prompt de-escalation of antibiotics once an organism is identified and/or the patient 
shows clinical improvement. If no organism is identified and there is persistent clinical 
deterioration in the setting of broad spectrum antibiotics, antifungals should be 
considered123. Measures to prevent superinfections (secondary infections that occur on 
top of a primary infection) should be implemented in patients with ACLF, including 
bundles of prevention and control of ventilator-associated pneumonia and catheter-
related bactereamia and urinary tract infections, hand hygiene, barrier precautions and 
avoiding unnecessary instrumentation124.  
Infected and non-infected patients admitted with ACLF are highly predisposed to 
developing new bacterial infections during hospitalization (J. Fernández, unpublished, 
CANONIC study). These infections act as ‘second hit’ of the syndrome. Prevention, 
early diagnosis and treatment of these second infections, therefore, is a major issue in 
ACLF.  
 
[H3] Anti-HBV therapy 
Reactivation of HBV is a frequent precipitating event of ACLF in cirrhotic patients in 
Asia. Antiviral treatment in patients with hepatitis B related ACLF improves liver 
function and increases short and long-term survival119–121,125,126. Therefore, early 
treatment with the antiviral agents (lamivudine, tenofovir, entecavir or telbuvidine) 
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should be started as soon as possible121,127.  
 
[H3] Immunomodulation  
Patients with ACLF might benefit from treatments aimed at restoring immune function, 
such as albumin, N-acetylcysteine and G-CSF117,128. Indeed, results from a recent 
randomized-controlled trial suggest that the administration of G-CSF prevents the 
development of sepsis and improves short-term survival in patients without severe 
forms of ACLF, who did not have sepsis, cerebral failure or  multi-organ failure128. G-
CSF is thought to act by mobilizing stem cells from the bone marrow to the periphery, 
including the liver, thus improving liver regeneration.   
[H3] Renal dysfunction and renal failure. 
Acute kidney injury (AKI) is the most frequent organ failure in ACLF8,129. Common 
causes of AKI include pre-renal, intrinsic causes and HRS129. Management of AKI 
differs depending on the underlying aetiology, and urinary biomarkers are helpful in 
identifying the cause of AKI129,130. Volume resuscitation with crystalloids and/or albumin 
should be used in patients with pre-renal AKI (impairment in renal function related to 
hypovolemia, i.e. excessive diuretic treatment). Terlipressin or norepinephrine are first 
choice treatment for HRS combined with volume expansion with albumin129. 
Terlipressin or norepinephrine are given to reduce the splanchnic arterial vasodilation 
causing systemic circulatory dysfunction and renal vasoconstriction in HRS. The effect 
of albumin was initially thought to be due to plasma volume expansion. However, a 
potential effect of albumin modulating the systemic inflammation of patients with ACLF 
in has recently been proposed7,105. Renal replacement therapy is used as a bridge to 
liver transplant or liver-kidney transplant in patients with severe AKI, although the dose 
and timing of dialysis has not been fully studied 129 .  
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[H3] Cardiovascular failure.  
As in management of sepsis, aggressive volume resuscitation and initiation of 
vasoconstrictor agents (i.e. norepinephrine)  to maintain an adequate blood pressure 
for organ perfusion is critical to counter the vasodilatory state that occurs with 
ACLF14,131. The goal mean arterial pressure is >60mmHg, and careful attention should 
be made to volume administration with crystalloids given the predisposition of volume 
overload in cirrhotic patients118. Colloids, including albumin, may also trigger volume 
overload. Terlipressin or vasopressin can be used as an adjunctive agent. There is also 
growing evidence that adrenal insufficiency in ACLF can further compromise 
haemodynamics132. Although still controversial, evaluation for adrenal insufficiency can 
be done by measuring random cortisol levels in the morning. If these levels are 
indeterminate, adrenal insufficiency can be confirmed with a ACTH test, which 
estimates the response of the adrenal glands to stress.  
 
[H3] Brain dysfunction and brain failure. 
Treatment of encephalopathy with tap water enemas, lactulose and oral non-
absorbable antibiotics (rifaximin, neomycin), by improving the level of consciousness, 
can prevent bronchial aspiration, aspiration pneumonias and respiratory failure14. It is 
important to titrate lactulose dose and enemas appropriately to prevent hypovolaemia 
that results from diarrhoea and to prevent hypernatremia (rise in serum sodium) that 
results from lactulose. Goal stool output in a day should be 3-4 bowel movements133. 
Lower stool output is insufficient to reduce the intestinal production of ammonia and to 
increase ammonia clearance from blood. Higher stool output may induce 
hypernatremic dehydration. Patients with grade III-IV encephalopathy should be 
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intubated, as they have a high risk of experiencing bronchial aspiration (i.e. of saliva or 
gastric fluid). Intra-craneal pressure monitoring and the use of mannitol is not 
recommended in these patients as cerebral oedema and intra-cranial hypertension are 
exceptional in patients with hepatic encephalopathy associated to ACLF12. 
 
[H3] Coagulopathy. 
Coagulopathy in patients with ACLF is often difficult to manage in the setting of 
fluctuations between a prothrombotic and an ineffective haemostatic state134,135. In the 
setting of active bleeding and severe coagulopathy, transfusions of platelets, 
cryoprecipitate (a frozen blood product prepared from plasma used to elevate 
fibrinogen levels) and blood should be considered. However, patients should not be 
prophylactically transfused with plasma for an elevated INR. Patients with portal vein 
thrombosis may require anticoagulant therapy to prevent recurrent variceal bleeding. 
 
[H2] Intensive care and extracorporeal liver support devices  
Admission to critical care units is mandatory in case of vascular, respiratory or brain 
failure and recommended in those with renal failure. Patients with liver and coagulation 
failure can still be treated in regular wards, but require strict clinical monitoring. In the 
CANONIC study8, 50% of the patients with ACLF were admitted to the intensive care 
unit (86% of those had ACLF grade 3). Owing to the high mortality rate in patients with 
ACLF, treatments able to bridge the time between admission of patients with severe 
disease (ACLF grades 2 or 3 at 3-7 days following admission) to liver transplantation 
are, therefore, clearly needed. 
Extracorporeal liver support systems are potential treatments for ACLF136,137. 
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Bioartificial liver support systems use hollow-fibre bioreactors containing hepatic 
cells to support the metabolic and synthetic function of the diseased liver. 
Currently, only tumour hepatocyte or porcine hepatocyte lines (the ELAD® and 
the HepAssist® 2000 systems) are available. A recent randomized trial 
comparing ELAD versus standard medical treatment did not find any significant 
effect in survival136. Non-biological systems consist in albumin dialysis 
techniques and are based on the capacity of this molecule to remove water 
insoluble substances and pro-inflammatory molecules (such as PAMPs and 
reactive oxygen species) retained in plasma as a consequence of liver failure 
and systemic inflammation105. Moreover, the physiology albumin function is 
markedly impaired in patients with decompensated cirrhosis due to severe 
oxidation of the molecule by endogenous reactive oxygen species, alterations in 
its molecular structure, and saturation of other binding sites by water insoluble 
substances produced and/or retained as consequence of liver failure (i.e. 
bilirubin, bile salts, drugs). Three different albumin dialysis systems are currently 
available: the molecular adsorbent and recirculating system (MARS®), the 
fractionated plasma separation and absorption (FPSA®) system and single-pass 
albumin dialysis (SPAD®). MARS, the system most extensively evaluated in 
ACLF, improves systemic haemodynamics and severe hepatic 
encephalopathy136,137. Two large randomized multicentre studies, however, failed 
to show an improvement in survival using MARS138,139Finally, an artificial liver 
device (called the University College London-Liver Dialysis Device) aimed at 
removing and replacing the dysfunctional albumin of patients with cirrhosis and 
reducing circulating endotoxemia is currently under evaluation140 . Plasma 
exchange, a detoxification system that increases survival in patients with acute 
liver failure141, improves hepatic encephalopathy and liver function in non-
randomized studies in patients with ACLF.  
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[H2] Liver transplantation 
Liver transplantation represents the only definitive therapeutic option for patients with 
ACLF. Very few studies, however, have assessed its feasibility, selection criteria 
(indications and contraindications), timing and efficacy96,142–148. In contrast to patients 
with acute liver failure, patients with ACLF cannot currently be included in the high-
urgency transplantation list. Moreover, since the clinical course of ACLF evolves 
rapidly, the timeframe for evaluation and listing is frequently very short. Advanced age, 
active alcoholism, uncontrolled infections and multi-organ failure are the main reasons 
for contraindication to transplantation or delisting. There is general agreement in 
considering that transplantation must be avoided in patients with severe circulatory or 
respiratory failure and ongoing sepsis. By contrast, for the majority of experienced 
centres, organ support (renal replacement therapy and mechanical ventilation) does 
not contraindicate transplantation in ACLF. Current data indicate that less than half of 
patients with ACLF are listed and that the procedure is feasible in only 10-25% of 
patients, since >50-70% of the listed patients die on the waiting list147. A recent US 
study showed that patients with cirrhosis, ACLF and high MELD score (>40) have 
higher waiting-list mortality (almost two-fold higher) than status 1A candidates (patients 
with acute liver failure) 145 . Defining criteria to select and prioritize patients with ACLF 
on the waiting list will help to improve outcomes by providing timely liver 
transplantation. Several studies show that both living donor liver transplantation and 
deceased donor transplantation offer similar results in this setting146–148. The reported 
outcome of patients transplanted for ACLF is good (Figure 6), ranging between 74% 
and 90% at 5 years, a number similar to that observed in patients transplanted for other 
indications96,144–148.  
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[H2] Management algorithm   
The three new scoring systems derived from the CANONIC study, the CLIF-C OF 
score (or CLIF-SOFA score), CLIF-C ACLF score and CLIF-C AD score, can be used 
to risk stratify cirrhotic patients with acute decompensation, to indicate early liver 
transplantation and to assess intensive care unit treatment futility (Figure 7)20,98. The 
prognosis in ACLF depends not only on the number of organ failures or the CLIF-C 
ACLF score at diagnosis, but also on the early response to treatment96. As nearly 20% 
of patients with ACLF grade 3 improve after treatment, patients with ≥3 organ failures 
should be admitted to the intensive care unit and receive unrestricted organ support for 
a short period of time (3-7 days). The persistence of ≥3 organ failures after this 
intervention may lead to the need to consider a limitation in life sustaining treatments 
since a fatal outcome is almost invariable in the absence of ‘salvage’ liver 
transplantation19. A high CLIF-C ACLF score (>64 points) after initial intervention (at 
day 3-7) has also been suggested as a potential futility rule in patients without 
possibilities of early liver transplantation96(. However, these criteria require further 
validation. Patients who are potential candidates for early liver transplantation, 
including living donor liver transplantation, must not be limited in their treatment. In 
those without options for transplantation, scores and a pragmatic case-by-case 
evaluation should be used for the decision.  
 
[H2] Regenerative therapy 
A few studies have evaluated the effect of G-CSF therapy in small groups of patients 
with ACLF128,149,150.This cytokine mobilizes bone marrow-derived stem cells, restores 
neutrophil function and promotes hepatic regeneration. Its administration in non-severe 
forms of ACLF reduces the risk of developing organ failure(s) and sepsis and improves 
survival. G-CSF therapy seems to be ineffective in patients with sepsis and in those 
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with more severe forms of ACLF. Hepatocyte and stem cell transplantation have also 
been proposed as potential treatments in ACLF151.  
 
[H1] Quality of life  
Following dismissal from hospital, patients recovering from ACLF may return to 
functioning in their community, receive a liver transplant, be sent to intermediate care 
facilities like a nursing home, or be re-hospitalized. The 30-day hospital readmission 
rate is approximately 25%152. In the long-term follow-up of 6 months in the 
NACSELD study, 27% of patients died, 14% were transplanted and 59% were alive 
without liver transplantation153. After discharge, 45% of patients had subsequent 
infections. Patients who had repeat infections were older and were more likely to use 
proton pump inhibitors, rifaximin or prophylactic therapy for SBP with 
norfloxacin154,155. In these last three circumstances predisposition to bacterial 
infections are probably related to gut dysbiosis or colonization by drug multi-resistant 
bacteria. Of critical importance to note, patients with infection related ACLF were 
more likely to be delisted for liver transplantation.  
 
[H1] Outlook 
[H2] ACLF definition  
The challenge of obtaining a universal definition of ACLF is an important issue. 
Differences between the APASL and Western definitions, however, are too important to 
be solved by consensus agreements alone. These definitions differ not only in terms of 
the characteristics of the patients, diagnostic criteria and clinical course but also, and 
most importantly, in the conceptual view of the disease. The APASL conference 
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definition postulates that the sequence of events in ACLF starts with a hepatic insult 
that causes acute liver failure and, as a consequence, extra-hepatic organ failure(s). By 
contrast, the Western definition relies on the concept that the acute impairment in liver 
function — which, if intense is defined as liver failure — develops simultaneously to an 
impairment in the function of other organs — which if intense are defined also as organ 
failures — as a consequence of an extrahepatic mechanism. These mechanisms could 
include intense systemic inflammation related to a massive release of DAMPS from the 
diseased liver (in the case of acute alcoholic hepatitis, viral hepatitis or DILI) or of 
PAMPs (by invading bacteria in the case of sepsis, or from the intestinal microbiota in 
patients without clear precipitating events). Such controversy can only be solved by 
promoting research in this outstanding new syndrome.  
 
[H2] Clinical challenges 
Investigations of ACLF have generally been performed after the diagnosis of the 
syndrome. As such, there are few data within the critical period prior to ACLF 
development. Prospective observational studies within this period are, therefore, 
essential, particularly those assessing biomarkers or panels of biomarkers of systemic 
inflammation that could be of value as predictors of treatment response and survival. 
Liver pathology in ACLF has also been insufficiently investigated. In patients with 
cirrhosis due to HBV infection, ACLF occurs in the setting of sub-massive hepatic 
necrosis27. In patients with alcoholic cirrhosis and active alcoholism, severe alcoholic 
hepatitis superimposed on cirrhosis is probably the predominant liver histology. Finally, 
two recent studies have reported severe ductular bilirubinostasis and cholestasis, a 
lesion also seen in non-cirrhotic patients with sepsis, as an specific lesion in 
ACLF156,157.  
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[H2] Insights into pathophysiology 
Sequential studies of the innate and adaptive immune system function prior to and after 
ACLF are lacking. Such studies are essential to understand the mechanism of ACLF. 
Moreover, the immune system function might change during the clinical course of the 
syndrome. As it occurs in sepsis158, an initial activation of the immune system in ACLF 
might be followed by a period of immunosuppression which would favour further 
bacterial translocation and progression of organ failure(s).  
The mechanism of organ failure in ACLF is of major interest. Renal failure in cirrhosis is 
considered to be secondary to systemic circulatory dysfunction and impaired renal 
perfusion. However, recent evidence from studies in sepsis suggest that renal failure 
might also be a consequence of a direct effect of renal inflammation, which impairs 
renal microcirculation and cell function159. In fact, there is evidence that inflammation 
might be involved in the pathogenesis of cardiac dysfunction, encephalopathy, relative 
adrenal insufficiency and pulmonary dysfunction in cirrhosis7.  
A major difficulty for research in ACLF is the lack of appropriate animal models. 
Carbon-tetrachloride induced cirrhosis in rats is an excellent model of cirrhosis but 
animals die prior the development of extra-hepatic organ failure160. Bile-duct ligated 
rats represent an acute model of liver failure and ascites and, in combination with the 
acute intra-peritoneal administration of LPS, have been used as a model of ACLF161. 
However, this model differs markedly from human cirrhosis and no extra-hepatic organ 
failure has been documented.  
 
[H2] Treatment  
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The recognition of systemic inflammation as the main mechanism of ACLF opens new 
fields in the design of new therapeutic procedures. This knowledge will promote the 
development of new artificial liver support systems capable of removing not only 
potentially harmful molecules retained as a consequence of organ failure but also pro-
inflammatory molecules that cause ACLF. Total plasma exchange141 is clearly 
alternative method to remove PAMPs, DAMPs and free radicals.  
A major issue in the management of ACLF, however, is prevention. There are three 
potential effective treatments that should be explored. The first consists in the 
prevention of bacterial translocation by long-term oral administration of poorly 
absorbable antibiotics107,110,162. Long-term weekly administration of intravenous albumin 
is the second approach. Preliminary data indicate that this technique prevented 
bacterial infections, AKI and hepatic encephalopathy and improved survival in a large 
Italian randomized controlled trial in patients with decompensated cirrhosis163. Finally, 
recent investigations have suggested a central role for defective bile acid receptor (also 
called farnesoid X-activated receptor, FXR) signalling in hepatic inflammation and 
intestinal bacterial translocation, factors which are known to shape ACLF164–166. 
Obeticholic acid is a potent FXR-agonist. Recent studies in animals have demonstrated 
that it lowers portal hypertension and improves bacterial translocation 165,166 suggesting 
that it might be of potential benefit in patients with ACLF. 
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Box 1. The main definitions of ACLF.  
[H1] The Asian Pacific Association for the Study of the Liver (APASL) definition.  
For patients with compensated cirrhosis or with any kind of non-cirrhotic chronic liver 
disease, except isolated steatosis (definition first made in 2004 and revised in 
2009)11,12: Acute-on-chronic liver failure (ACLF) is the result of an acute direct hepatic 
insult (hepatotropic viral infections, active alcohol consumption or drug-induced liver 
injury) that causes liver failure. Liver failure is defined as jaundice (serum bilirubin ≥5 
mg per dl) and coagulopathy (international normalized ratio ≥1.5 or prothrombin activity 
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<40%). This liver failure is complicated within 4 weeks by clinical ascites and/or 
encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver 
disease (including cirrhosis). Both compensated cirrhosis and non-cirrhotic chronic liver 
disease (non-alcoholic fatty liver disease-related chronic hepatic injury or chronic 
hepatitis with fibrosis or fibrosis due to other reasons) qualify as chronic liver disease. 
Bacterial infections are not considered hepatic insults. Patients with cirrhosis and 
known prior decompensation (jaundice, encephalopathy or ascites) who develop acute 
deterioration of their clinical status that is either related or unrelated to precipitating 
events are considered to have acute decompensation but not ACLF.  
 
[H1] The European Association for the Study of the Liver-Chronic Liver Failure 
(EASL-CLIF) Consortium definition 
For patients with cirrhosis (2013)8: ACLF is the development of acute decompensation 
of cirrhosis (defined by the development of ascites, encephalopathy, gastrointestinal 
haemorrhage and/or bacterial infection) associated with either a single organ failure 
(single renal failure or other single non-renal organ failure if associated with renal 
and/or cerebral dysfunction) or multiple organ failures.  
 [H1] Other definitions 
 R. Jalan and R. Williams definition (2002)10 
 The Chinese Medical Association (CMA) definition (2013)15 
 The American Association for the Study of Liver Diseases (AASLD) and the 
European Association for the Study of the Liver (EASL) definition (2014)14 
 North-American Consortium for the Study of End Stage Liver Disease 
(NACSELD) definition (2014)13 
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Box 2 | ACLF grades  
[H1] No ACLF 
 This category includes patients who either: 
 Do not have any organ failure  
 Have a single organ failure that does not involve the kidneys with serum 
creatinine <1.5 mg per dL and no hepatic encephalopathy  
 Have single cerebral failure with serum creatinine <1.5 mg per dL 
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[H1] ACLF grade 1 
ACLF grade 1 is diagnosed with one of the following:  
 Single kidney failure  
 Single liver, coagulation, circulatory or lung failure that is associated with serum 
creatinine of 1.5-1.9 mg/dL and/or hepatic encephalopathy grades 1 or 2  
 Single cerebral failure with serum creatinine between 1.5 and1.9 mg per dL 
[H1] ACLF grade 2  
ACLF grade 2 is diagnosed when there are two organ failures of any combination 
[H1] ACLF grade 3  
ACLF grade 3 is diagnosed when there are three or more organ failures.  
 
 
 
Figure 1 | The clinical course of cirrhosis Acute-on-chronic liver failure (ACLF) can 
develop at any stage from compensated to decompensated cirrhosis, and can involve 
hepatic or extrahepatic precipitating events, although a considerable proportion of 
patients have no identifiable triggering event. In this figure, paracentesis means ‘large 
volume paracentesis (>5 litres)’. Acute decompensation of cirrhosis defines the acute 
development of clinically evident ascites, hepatic encephalopathy, gastrointestinal 
haemorrhage or any combination of these in patients with or without prior history of 
these complications. Although bacterial infections are not specific complications of 
cirrhosis, they are considered as such in patients with prior history of ascites, 
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haemorrhage or encephalopathy because of their high prevalence and their association 
with abnormalities related to cirrhosis, including bacterial translocation and impaired 
leukocyte function1–8 . DILI, Drug-induced liver injury; LT, liver transplantation; TIPS, 
transjugular intrahepatic portosystemic shunt. Figure courtesy of Jordi Bozzo (Scientific 
Publication Manager. Grifols SA ]  
 
Figure 2 | Different ACLF definitions capture different patient populations. A) The 
proportion of patients diagnosed with acute-on-chronic liver failure (ACLF) according to 
the Asia-Pacific Association for the Study of the Liver (APASL) definition (orange), the 
European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) 
Consortium definition  (red), and both definitions (blue). Data are from a large series of 
patients from Korea 35 (1,470 patients of which 1,352 with cirrhosis with or without prior 
history of decompensation) and from the CANONIC study conducted in Europe 8. B) 
The 90-day probability of survival in both series of patients depending on the ACLF 
diagnosis. Figures with European data derive from unpublished results of the 
CANONIC study provided by the Data Management Center of the European 
Foundation for the Study of Chronic Liver Failure. Figures with the Korean data 
adapted from PLoSOne, 2016 Jan 20;11(1):e0146745. doi: 10.1371. Kim TH et al, 
Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified 
definition. Copyright (2015). 
 
Figure 3 | Structural feature recognition of bacteria and induction of the 
inflammatory response. A) Examples of pattern-recognition receptors (PRRs) that 
detect unique molecular structures of bacterial pathogen-associated molecular patterns 
(PAMPs) and their sub-cellular localizations. PRRs for bacterial ligands include Toll-like 
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receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLRs), retinoic acid-inducible gene (RIG)-I (a member of the RIG-I-like receptor 
family) and cytosolic DNA sensors (including interferon, gamma-inducible protein 16 
(IFI16), absent in melanoma 2 (AIM2), and cyclic GMP-AMP synthase (cGAS)). 43–48,167. 
B) An example of PRR-mediated inflammation is the activation of inflammatory 
signalling pathways by extracellular and intracellular lipopolysaccharide (LPS). 
Detection of extracellular LPS by TLR4 engages two intracellular signalling conduits: 
the MyD88 pathway (purple), involving the adaptor Toll/interleukin-1 receptor domain-
containing adapter protein (TIRAP); and the TIR-domain-containing adaptor protein 
inducing interferon (IFN)-β (TRIF) pathway (green), involving the adaptor TIR domain-
containing adapter molecule 2 (TICAM2) 43. The MyD88 pathway via TNF receptor-
associated factor 6 (TRAF6) stimulates different kinases (grey), inhibitor of nuclear 
factor (NF)-B (IB) kinase (IKK) and mitogen-activated protein kinases (MAPKs) that 
activate master transcription factors (TFs), NF-B and activator protein-1 (AP-1), 
respectively. The MyD88 pathway also activates the TF interferon (IFN) regulatory 
factor 5 (IRF5). These activated TFs contributes to the induction of an array of pro-
inflammatory genes such as tumour necrosis factor (TNF) and interleukin 6 (IL6), and 
anti-inflammatory genes such as IL10, IL1RN. The TRIF pathway involves TRAF3 to 
activate the TF, IRF3, which then contributes with other TFs to the induction of type 1 
IFNs 43 . Intracellular LPS is recognized by the inflammatory caspases (caspase-4/5 in 
humans and caspase-11 in mice) that stimulate the non-canonical NOD-, leucine-rich 
repeat (LRR)- and pyrin domain (PYD)-containing protein 3 (NLRP3) inflammasome 
167,168. This results in the activation of another inflammatory caspase-1 (not shown) 
which promotes cleavage of IL-1β and IL-18 167,168 . Activation of caspase-4/5 by 
intracellular LPS can trigger a programmed cell death called pyroptosis 169.  
Figure 4 | Intestinal dysbiosis and bacterial translocation. Cirrhosis is associated 
with quantitative differences (bacterial overgrowth) and compositional changes of the 
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gut microbiota, so called dysbiosis. Several factors might contribute to dysbiosis of the 
gut microbiota during cirrhosis including diet, use of antibiotics, decreased bile flow and 
intestinal motility, changes in gastric pH and impaired mucosal immunity. A second 
important feature of that patients with cirrhosis also show is translocation of bacteria. 
Disruption of tight junctions allows pathogen-associated molecular patterns (PAMPs) 
and possibly other microbial metabolites to use the paracellular route between adjacent 
intestinal epithelial cells for translocation. Intestinal permeability is already increased in 
pre-cirrhotic stages, whereas translocation of viable bacteria is a characteristic of 
cirrhosis, in particular during decompensation. Bacteria most likely use the transcellular 
route (transcytosis) through epithelial cells. PAMPs might also activate immune cells 
including monocytes, macrophages and T-cells in the lamina propria of the intestine 
leading to secretion of inflammatory mediators. Cytokines such as tumour necrosis 
factor (TNF), interleukin (IL)-6, IL-17, nitric oxide (NO) and interferon (IFN)-γ are 
increased in the intestine of patients or animal models with cirrhosis 76–78. Several of 
these mediators are known to contribute to a dysfunction of tight junctions. On the 
other hand, the intestinal immune surveillance response might be impaired to remove 
translocated bacteria in the lamina propria. 
 
Figure 5 | Relationship between organ failure and mortality in ACLF. 28-day 
mortality rates of patients with decompensated cirrhosis with (red bars) and without 
(green bars) acute-on-chronic liver failure (ACLF) according to the diagnostic criteria 
proposed in the CANONIC study8. Patients are divided into the following categories: 
Patients with no organ failure (OF); patients with single non-kidney organ failure 
without kidney dysfunction (KD,serum creatinine 1.5-1.9 mg per dL) or cerebral 
dysfunction (CD, grade 1-2 hepatic encephalopathy); patients with single kidney failure; 
patients with single non-kidney organ failure with KD and/or CD; patients with two 
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organ failures; and patients with ≥3 organ failures. Figure derived from the CANONIC 
study, adapted from Gastroenterology, 144 Moreau, R et al., Acute-on-chronic liver 
failure is a distinct syndrome that develops in patients with acute decompensation of 
cirrhosis., 1426-1437, Copyright (2013). 
Figure 6 | Liver transplant increases survival of patients with. Survival probability 
curves of patients with grades 2 or 3 ACLF at day 3-7 following diagnosis who were 
submitted to early (less than 28-day) liver transplantation (red curve; n=21) and 
patients with the same ACLF grades who did not receive a liver transplant (blue curve; 
n=120)96. Figures over the curves show the 28-day, 90-day and 6-month probability of 
survival. Reprinted from Hepatology, 62 Gustot T et al., Clinical course of acute-on-
chronic liver failure syndrome and effects on prognosis., 243-252, Copyright (2015).  
Figure 7 | Proposed algorithm for management of patients with ACLF or 
decompensated cirrhosis. A proposed management strategy for patients with acute-
on-chronic liver failure (ACLF) based on mortality rate data from the CANONIC study96 
.The first step is the assessment of ACLF grade at days 3-7 after initiation of medical 
management, including organ support(s). Liver transplantation should be assessed in 
all patients with ACLF because of high 90-day mortality rates (>20%). Liver 
transplantation should be performed as early as possible in patients with ACLF grade 2 
and grade 3 since they are at great risk of short-term (28-day) mortality. In the case of 
contraindication of liver transplantation the presence of four or more organ failures 
(OFs) or Chronic Liver Failure (CLIF)-C ACLF score >64 at days 3-7 after diagnosis 
could indicate the futility of care. Reprinted from Hepatology, 62 Gustot T et al., Clinical 
course of acute-on-chronic liver failure syndrome and effects on prognosis., 243-252, 
Copyright (2015).  
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Table 1 | Selected studies on the prevalence of ACLF 
Country or 
Region 
Diagnostic 
criteria 
Population Prevalence 
of ACLF 
Refs 
China EASL-CLIF 890 patients 
hospitalized with 
decompensated 
cirrhosis due to chronic 
hepatitis B 
34%§  24 
China EASL-CLIF 1,397 patients 
hospitalized with 
decompensated 
cirrhosis due to chronic 
hepatitis B 
30%§  97 
North 
America   
NACSELD* Patients with 
decompensated 
cirrhosis and acute 
bacterial infections 
24% 13 
Scandinavia EASL-CLIF  Patients with cirrhosis 
(from a population of 
600,000) 
24%ǂ 170 
Europe  EASL-CLIF  1,343 CANONIC study 
participants 
30.9%§  8 
*Patients with decompensated cirrhosis and bacterial infections who develop two organ 
failures. §At enrolment and during hospitalization.ǂ Infection-related ACLF diagnosed 
between 2001 and 2010. EASL-CLIF, European Association for the Study of the Liver-
Chronic Liver Failure; NACSELD, North -American Consortium for the Study of End 
Stage Liver Disease. 
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Table 2 | CLIF-C OF score20.  
Organ or system Sub-score = 1 Sub-score = 2 (OR 
vs sub-score 1 
(95%CI) 
Sub-score = 3§ (OR 
vs sub-score 1 
(95%CI) 
Liver 
 
Bilirubin <6mg 
per dL 
 
6≤ bilirubin ≤12mg 
per dL 
(OR: 2.6 (1·6 – 4.3)) 
Bilirubin >12mg per 
dL§ 
(OR: 7.1 (4.7 – 10.7))  
Kidney 
 
Creatinine <2 mg 
per dL 
2≤ creatinine <3.5 
mg per dL § (OR: 
3.8 (2.3 – 6·3))§ 
Creatinine ≥3.5 mg 
per dL 
or renal replacement§ 
(OR: 15.5 (8.9 – 26.8))  
Brain 
 
West-Haven 
HE171 grade 0 
West-Haven HE 
grade 1-2(OR: 2·1 
(1·4 – 3·2)) 
West-Haven HE grade 
3-4*§ 
(OR: 9·7 (5·9 – 16·1)) 
Coagulation 
 
INR <2·0 2·0 ≤ INR <2·5 
(OR: 5·2 (3·4 – 
7·9)) 
INR ≥2·5§ 
OR: 7·5 (4·6 – 12·3) 
Circulation 
 
MAP ≥70 mmHg MAP <70 mmHg 
(OR: 2·6 (1·6 – 
4·3)) 
Use of vasopressors§ 
OR: 9·2 (5·2 – 16·4) 
Respiratory system 
 
 
PaO2/FiO2 >300 
or 
SpO2/FiO2 >357 
 
200< PaO2/FiO2 
≤300 
or 
>214 SpO2/FiO2 
≤357 
(OR: 2·7 (1·7 – 
4·2)) 
 
PaO2/FiO2 ≤200# 
or 
SpO2/FiO2 ≤214#§ 
(OR: 6·4 (3·1 – 13·2)) 
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The odds ratio (OR) describes the increase in the risk of 28-day mortality compared with the low 
risk category for each organ system and sub-score. HE, Hepatic encephalopathy; INR, 
International normalized ratio; FIO2, fraction of inspired oxygen; PaO2, partial pressure of 
arterial oxygen; SpO2, pulse oximetric saturation; MAP, Mean arterial pressure. §Criteria for 
diagnosing organ failures.*Patients submitted to mechanical ventilation due to HE and not to a 
respiratory failure were considered as presenting a cerebral failure (cerebral sub-score=3). # 
Other patients enrolled in the study with MV were considered as presenting a respiratory  
(respiratory sub-score=3). Adapted from J Hepatol, 61 Jalan R et al., Development and 
validation of a prognostic score to predict mortality in patients with acute-on-chronic liver 
failure., 1038-1047, Copyright (2014).  
CLIF-C OF, CLIF-C Organ failure 
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Table 3 | ACLF grade and mortality in the CANONIC study8  
Category 28-day mortality 90-day mortality 
No ACLF 1.9% 10% 
ACLF (total) 33% 51% 
ACLF grade 1 23% 41% 
ACLF grade 2 31% 55% 
ACLF grade 3 74% 78% 
Adapted from Gastroenterology, 144 Moreau, R et al., Acute-on-chronic liver failure is a 
distinct syndrome that develops in patients with acute decompensation of cirrhosis., 
1426-1437, Copyright (2013). 
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Table 4 | Proportion of patients with potential precipitating events at enrolment in 
the CANONIC Study8 .  
Precipitating 
event 
Proportion 
without  
ACLF 
(n=1040) 
Proportion 
with ACLF 
(n=303) 
P value§ 
Bacterial infection 21.8% 32.6% <0.0001 
Gastrointestinal 
bleeding 
17.3% 13.2% ns 
Active alcoholism* 14.9% 24.5% 0.0002 
Other event ** 3.5% 8.6% 0.0002 
No event *** 58.9% 43.6% <0.0001 
Any event *** 41.1% 56.4% <0.0001  
>1 event *** 5.7% 13.5% <0.0001 
§ P value compares (Chi-square test) the prevalence of potential 
precipitating events between patients with and without ACLF at enrolment 
in the CANONIC study. Bacterial infection and active alcoholism were 
significantly more frequent in patients with than in those without ACLF, 
suggesting that they were associated with the development of the 
syndrome. This was not the case for gastrointestinal bleeding*Within 3 
months prior to inclusion. **Other precipitating events include large volume 
paracentesis without i.v. administration of albumin (to prevent post-
paracentesis circulatory dysfunction), transjugular intrahepatic 
portosystemic shunt (which is used to treat portal hypertension), major 
surgery, acute hepatitis (caused by viral infection, ischemia, or drug-
induced liver injury) and acute alcoholic hepatitis. Liver biopsy was required 
for the diagnosis of acute alcoholic hepatitis in the CANONIC protocol but 
many patients with active alcoholism had a clinical picture suggestive of 
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this diagnosis.*** Bacterial infections, active alcoholism or other 
precipitating events. ns, not significant. Adapted from Gastroenterology, 
144 Moreau, R et al., Acute-on-chronic liver failure is a distinct syndrome 
that develops in patients with acute decompensation of cirrhosis., 1426-
1437, Copyright (2013). 
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Third party rights table 
Category Reference  
number 
 
Figure 2 35 PLoSOne, 2016 Jan 20;11(1):e0146745. doi: 10.1371. Kim TH et al, 
Characteristics and discrepancies in acute-on-chronic liver failure: 
need for a unified definition.Copyright (2015 
Figure 5 8 Gastroenterology, 144 Moreau, R et al., Acute-on-chronic liver failure 
is a distinct syndrome that develops in patients with acute 
decompensation of cirrhosis. 1426-1437, Copyright (2013). 
 
Figure 6 96 Hepatology, 62 Gustot T et al., Clinical course of acute-on-chronic 
liver failure syndrome and effects on prognosis., 243-252, Copyright 
(2015). 
Figure 7 96 Hepatology, 62 Gustot T et al., Clinical course of acute-on-chronic 
liver failure syndrome and effects on prognosis., 243-252, Copyright 
(2015). 
Table 2 20 J Hepatol, 61 Jalan R et al., Development and validation of a 
prognostic score to predict mortality in patients with acute-on-chronic 
liver failure., 1038-1047, Copyright (2014).  
 
Table 3 8 Gastroenterology, 144 Moreau, R et al., Acute-on-chronic liver failure 
is a distinct syndrome that develops in patients with acute 
decompensation of cirrhosis., 1426-1437, Copyright (2013). 
 
Table 4 8 Gastroenterology, 144 Moreau, R et al., Acute-on-chronic liver failure 
is a distinct syndrome that develops in patients with acute 
decompensation of cirrhosis., 1426-1437, Copyright (2013). 
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